Novartis (NVS)
(Real Time Quote from BATS)
$98.99 USD
+1.26 (1.29%)
Updated May 7, 2024 02:00 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Novartis AG [NVS]
Reports for Purchase
Showing records 81 - 100 ( 474 total )
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 3.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 3123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 22123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 21123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 3.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 2123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 12123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended January 13.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 11123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 1123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 122122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended December 9.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D